NUPLAZID® Coverage, Cost & Financial Assistance

what Medicare Part D patients should know:

Shield with teal outline inside off-white bubble

$2,100 annual cap on out-of-pocket costs

In 2026, Medicare Part D limits out-of-pocket prescription drug costs to $2,100 for the year. Once a patient reaches that cap, they pay nothing more for covered drugs—including NUPLAZID—for the rest of the plan year.

The 2027 Medicare Part D annual out-of-pocket maximum is expected to increase to $2,400

https://www.medicare.gov/health-drug-plans/part-d

Spreading out prescription costs

The Medicare Prescription Payment Plan (MPPP) is a free, voluntary program that helps patients manage prescription drug costs. Instead of paying larger amounts up front, patients can spread smaller monthly payments throughout the year. Patients can enroll by phone, online, or by paper form through their plan.

https://www.medicare.gov/prescription-payment-plan/before-payment-option

Extra Help for prescription costs

Patients may qualify for Extra Help—a Medicare program that reduces or eliminates their Part D premiums, deductibles, and copays. In 2026, income limits are approximately $23,475 for an individual^†‡ and $31,725 for a two-person household.^†‡

The 2027 Medicare Part D annual income limits are expected to increase to $23,490 for an individual^†‡ and $32,460 for a two-person household.^†‡

^†Subject to change.

^‡These income limits are higher in Alaska and Hawaii.

https://www.medicare.gov/extrahelp

understanding other resources available to patients:

Available Nationally and in Your Area

Organization Name

Contact Information

Services Offered

CMS Medicare Plan Finder

www.medicare.gov/plan-compare

Compare Medicare drug plans, find coverage options, and estimate out-of-pocket costs.

Medicare Navigators

themedicarenavigators.com
1-810-740-2010

Free counseling on Medicare plan options, appeals, and enrollment. Available through SHIP (State Health Insurance-Assistance Programs).

State Health Insurance Assistance Program (SHIP)

shiphelp.com
1-877-839-2675

In-depth, one-on-one insurance counseling and assistance with Medicare.

CMS Medicare Plan Finder

www.medicare.gov/plan-compare

Compare Medicare drug plans, find coverage options, and estimate out-of-pocket costs.

Medicare Navigators

themedicarenavigators.com
1-810-740-2010

Free counseling on Medicare plan options, appeals, and enrollment. Available through SHIP (State Health Insurance-Assistance Programs.)

State Health Insurance Assistance Program (SHIP)

shiphelp.com
1-877-839-2675

In-depth, one-on-one insurance counseling and assistance with Medicare.

Important Safety Information and Indication for NUPLAZID^® (pimavanserin)

Indication

NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Important Safety Information

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
NUPLAZID is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson’s disease.

Contraindication: NUPLAZID is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Rash, urticaria, and reactions consistent with angioedema (e.g., tongue swelling, circumoral edema, throat tightness, and dyspnea) have been reported.
Warnings and Precautions: QT Interval Prolongation

NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval (e.g., Class 1A antiarrhythmics, Class 3 antiarrhythmics, certain antipsychotics or antibiotics).
NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions:

Coadministration with strong CYP3A4 inhibitors increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg taken orally as one tablet once daily.
Coadministration with strong or moderate CYP3A4 inducers reduces NUPLAZID exposure. Avoid concomitant use of strong or moderate CYP3A4 inducers with NUPLAZID.

Please read the full Prescribing Information, including Boxed WARNING, also available at NUPLAZIDhcp.com.

Dosage and Administration

Recommended dose: 34 mg capsule taken orally once daily, without titration, with or without food.

NUPLAZID is available as 34 mg capsules and 10 mg tablets.

coverage and financial support services.

Call us at 1-844-737-2223

coverage at a glance:

what Medicare Part D patients should know:

understanding other resources available to patients:

coverage at a glance:

ICD-10 diagnostic codes for Parkinson’s disease (PD) psychosis:

your PAM can provide patient insight reviews.

Independent Charitable Foundations (ICFs).**

Financial Assistance Foundations

get your patients started today.

1-844-737-2223

Important Safety Information

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS